Vigil Neuroscience (VIGL) News Today $1.70 +0.04 (+2.41%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Vigil Neuroscience, Inc. (NASDAQ:VIGL) Director Haeberlein Samantha L. Budd Purchases 12,000 SharesVigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) Director Haeberlein Samantha L. Budd purchased 12,000 shares of the firm's stock in a transaction dated Thursday, December 19th. The shares were bought at an average price of $1.71 per share, with a total value of $20,520.00. Following the purchase, the director now owns 12,000 shares in the company, valued at $20,520. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.December 19 at 7:44 PM | marketbeat.comBuy Rating for Vigil Neuroscience Inc: Confidence in Microglial Biology Strategy Amid Market ChallengesDecember 10, 2024 | markets.businessinsider.comInsider Buying: Vigil Neuroscience, Inc. (NASDAQ:VIGL) CEO Buys 5,000 Shares of StockDecember 6, 2024 | insidertrades.comEquities Analysts Issue Forecasts for VIGL FY2024 EarningsVigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - Equities researchers at William Blair issued their FY2024 earnings estimates for shares of Vigil Neuroscience in a report issued on Tuesday, December 3rd. William Blair analyst S. Schram forecasts that the company will earn ($2.00) per shareDecember 6, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN), Trevi Therapeutics (TRVI) and Vigil Neuroscience Inc (VIGL)December 5, 2024 | markets.businessinsider.comWilliam Blair Initiates Coverage of Vigil Neuroscience (VIGL) with Outperform RecommendationDecember 5, 2024 | msn.comVigil Neuroscience: Down On A Competitor's FailureDecember 3, 2024 | seekingalpha.comVigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest UpdateVigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) was the target of a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 736,700 shares, an increase of 51.3% from the October 31st total of 487,000 shares. Based on an average daily volume of 112,200 shares, the short-interest ratio is currently 6.6 days. Approximately 3.9% of the shares of the company are short sold.November 29, 2024 | marketbeat.comOptimistic Buy Rating for Vigil Neuroscience Amid Market OverreactionNovember 28, 2024 | markets.businessinsider.comPromising Potential of Vigil Neuroscience’s VG-3927 in Alzheimer’s Treatment with a Buy Rating and $17 Price TargetNovember 26, 2024 | markets.businessinsider.comVigil Neuroscience (NASDAQ:VIGL) Given "Market Outperform" Rating at JMP SecuritiesJMP Securities restated a "market outperform" rating and set a $22.00 target price on shares of Vigil Neuroscience in a research report on Tuesday.November 26, 2024 | marketbeat.comBullish Outlook on Vigil Neuroscience Inc. Amid Promising Clinical Data and Unique TREM2 Biology FocusNovember 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Joint (JYNT), Vigil Neuroscience Inc (VIGL) and Definitive Healthcare Corp (DH)November 9, 2024 | markets.businessinsider.comVigil Neuroscience Advances Key Clinical ProgramsNovember 9, 2024 | markets.businessinsider.comVigil Neuroscience (NASDAQ:VIGL) Price Target Raised to $24.00Wedbush boosted their price objective on Vigil Neuroscience from $23.00 to $24.00 and gave the stock an "outperform" rating in a research note on Friday.November 8, 2024 | marketbeat.comVigil Neuroscience's (VIGL) Buy Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $17.00 target price on shares of Vigil Neuroscience in a report on Friday.November 8, 2024 | marketbeat.comVigil Neuroscience, Inc. (NASDAQ:VIGL) has caught the attention of institutional investors who hold a sizeable 41% stakeNovember 8, 2024 | finance.yahoo.comVigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 8, 2024 | markets.businessinsider.comVigil Neuroscience to Present at Guggenheim Healthcare Innovation ConferenceNovember 5, 2024 | markets.businessinsider.comabrdn plc Makes New $799,000 Investment in Vigil Neuroscience, Inc. (NASDAQ:VIGL)abrdn plc purchased a new stake in Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 235,011 shares of the company's stock, valued at approximately $799,000. abrdn plcNovember 5, 2024 | marketbeat.comStifel Nicolaus Sticks to Its Buy Rating for Vigil Neuroscience Inc (VIGL)October 19, 2024 | markets.businessinsider.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)October 9, 2024 | prnewswire.comBuy Rating Affirmed for Vigil Neuroscience Inc Amid Promising Alzheimer’s Treatment PotentialOctober 9, 2024 | markets.businessinsider.comPoint72 Asset Management L.P. Buys New Position in Vigil Neuroscience, Inc. (NASDAQ:VIGL)Point72 Asset Management L.P. purchased a new position in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 1,485,000 shares of the company's stock, valuedOctober 2, 2024 | marketbeat.comEnsign Peak Advisors Inc Buys 166,442 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL)Ensign Peak Advisors Inc grew its stake in Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) by 72.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 395,116 shares of the company's stock after acquiringSeptember 29, 2024 | marketbeat.comVigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Down 20.3% in SeptemberVigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) was the recipient of a significant decrease in short interest in the month of September. As of September 15th, there was short interest totalling 546,600 shares, a decrease of 20.3% from the August 31st total of 685,800 shares. Based on an average daily volume of 488,600 shares, the days-to-cover ratio is currently 1.1 days. Approximately 2.7% of the company's shares are sold short.September 27, 2024 | marketbeat.comFDA lifts partial clinical hold on Vigil Neuroscience’s Phase I VG-3927 trialSeptember 20, 2024 | msn.comBuy Rating Affirmed for Vigil Neuroscience Inc. as FDA Lifts Clinical Hold and Phase 1 Trials Show PromiseSeptember 18, 2024 | markets.businessinsider.comVigil Neuroscience Says FDA Lifts Partial Hold Alzheimer's-Treatment TrialSeptember 17, 2024 | marketwatch.comVigil says FDA removed partial hold on Alzheimer’s candidateSeptember 17, 2024 | msn.comVigil Neuroscience, Inc.: Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927September 17, 2024 | finanznachrichten.deVigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927September 17, 2024 | globenewswire.comVigil Neuroscience to Present at Cantor Global Healthcare ConferenceSeptember 16, 2024 | globenewswire.comVigil Neuroscience (NASDAQ:VIGL) Trading Up 5%Vigil Neuroscience (NASDAQ:VIGL) Trading 5% HigherSeptember 10, 2024 | marketbeat.comVigil Neuroscience to Present at Upcoming September Investor ConferencesAugust 29, 2024 | globenewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)August 23, 2024 | prnewswire.comResearch Analysts Offer Predictions for Vigil Neuroscience, Inc.'s Q3 2024 Earnings (NASDAQ:VIGL)Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - HC Wainwright dropped their Q3 2024 earnings per share estimates for Vigil Neuroscience in a note issued to investors on Wednesday, August 14th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($August 16, 2024 | marketbeat.comVigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Down 20.4% in JulyVigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) saw a large drop in short interest in the month of July. As of July 31st, there was short interest totalling 884,100 shares, a drop of 20.4% from the July 15th total of 1,110,000 shares. Based on an average daily trading volume, of 563,800 shares, the short-interest ratio is currently 1.6 days. Approximately 5.2% of the company's stock are short sold.August 15, 2024 | marketbeat.comFY2027 EPS Estimates for Vigil Neuroscience, Inc. Reduced by HC Wainwright (NASDAQ:VIGL)Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - HC Wainwright lowered their FY2027 earnings estimates for shares of Vigil Neuroscience in a research note issued on Wednesday, August 14th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of $0.29 per share fAugust 15, 2024 | marketbeat.comBuy Rating Affirmed for Vigil Neuroscience Inc on Promising Drug Trials and Regulatory ProspectsAugust 15, 2024 | markets.businessinsider.comGuggenheim Trims Vigil Neuroscience (NASDAQ:VIGL) Target Price to $16.00Guggenheim cut their price target on shares of Vigil Neuroscience from $17.00 to $16.00 and set a "buy" rating for the company in a report on Wednesday.August 14, 2024 | marketbeat.comVigil Neuroscience, Inc.: Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 13, 2024 | finanznachrichten.deVIGL Stock Earnings: Vigil Neuroscience Beats EPS for Q2 2024August 13, 2024 | investorplace.comVigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 13, 2024 | globenewswire.comVigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology GeneticsAugust 1, 2024 | finance.yahoo.comVigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)July 31, 2024 | stockhouse.comVigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Down 48.4% in JulyVigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) saw a significant decline in short interest in July. As of July 15th, there was short interest totalling 1,110,000 shares, a decline of 48.4% from the June 30th total of 2,150,000 shares. Based on an average daily volume of 530,300 shares, the days-to-cover ratio is currently 2.1 days. Currently, 7.1% of the company's stock are short sold.July 26, 2024 | marketbeat.comBuy Rating Affirmed on Vigil Neuroscience’s VG-3927 Based on Positive Phase 1 Results and Strong Industry OutlookJuly 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vigil Neuroscience Inc. on Promising VG-3927 Phase 1 Study Results and Alzheimer’s Treatment Market PotentialJuly 25, 2024 | markets.businessinsider.comCoinDesk 20 Performance Update: XRP and NEAR Help Push Index UpwardJuly 25, 2024 | uk.finance.yahoo.com Get Vigil Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for VIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment (Ad)This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast. Click here for the ticker >>> VIGL Media Mentions By Week VIGL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VIGL News Sentiment▼1.300.60▲Average Medical News Sentiment VIGL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VIGL Articles This Week▼32▲VIGL Articles Average Week Get Vigil Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for VIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CCCC News Today FDMT News Today ITOS News Today ENGN News Today ATYR News Today ARTV News Today IKT News Today OCGN News Today LXEO News Today FATE News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VIGL) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vigil Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vigil Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
